{
  "0PQ.F": {
    "city": "Leiden",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "ProQR Therapeutics N.V.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PROQR THERAPEUTICS EO-,04",
    "state": null,
    "summary": "ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.",
    "website": "http://www.proqr.com",
    "zipcode": "2333 Ck"
  },
  "1AE.F": {
    "city": "Breda",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "argenx SE",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ARGENX SE EO -,10",
    "state": null,
    "summary": "argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.",
    "website": "http://www.argenx.com",
    "zipcode": "4811 AH"
  },
  "2GH.F": {
    "city": "Utrecht",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Merus N.V.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MERUS N.V.  EO -,09",
    "state": null,
    "summary": "Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 for the pancreatic and lung cancer, and other solid tumors. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat autoimmune disease. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore potential combination therapies or indication. Merus N.V. has collaborations and license agreement with Loxo Oncology at Lilly to discover and research novel T-cell re-directing bispecific antibodies. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.",
    "website": "http://www.merus.nl",
    "zipcode": "3584 CM"
  },
  "5C1A.F": {
    "city": "Amsterdam",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "Esperite N.V.",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ESPERITE N.V.",
    "state": null,
    "summary": "Esperite N.V., together with its subsidiaries, operates as a regenerative and predictive medicine company in the Netherlands, Spain, Italy, Switzerland, and internationally. It operates through four segments: Stem Cell, The Cell Factory, Genoma, and Other. The company collects, processes, and stores human adult stem cells from the umbilical cord blood and the umbilical cord. It also provides proteomics and genomics predictive medicines; and implements its proprietary technology for clinical grade production of autologous mesenchymal and stromal stem cells. In addition, it develops AGAATA, a diagnostic system based on the next generation sequencing technology, as well as allows laboratories to perform their own genetic analysis with the bioinformatics and methods developed by Genoma. The company's products portfolio includes Tranquility, a non-invasive prenatal test; and Cryosave's whole genome sequencing, carrier screening tests, and other products. Further, it engages in biobanking cord blood and cord tissue stem cells business. The company was formerly known as Cryo-Save Group N.V. and changed its name to Esperite N.V. in July 2014. Esperite N.V. was founded in 2000 and is headquartered in Amsterdam, the Netherlands.",
    "website": "http://www.esperite.com",
    "zipcode": "1016 BX"
  },
  "9EN.F": {
    "city": "Leiden",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Pharvaris N.V.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PHARVARIS N.V.  EO -,12",
    "state": null,
    "summary": "Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks; and PHVS719, a prophylactic extended-release tablet for HAE patients. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is headquartered in Leiden, the Netherlands.",
    "website": "http://pharvaris.com",
    "zipcode": "2333 CH"
  },
  "ARGX": {
    "city": "Breda",
    "country": "Netherlands",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "argenx SE",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "argenx SE",
    "state": null,
    "summary": "argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.",
    "website": "http://www.argenx.com",
    "zipcode": "4811 AH"
  },
  "ARGX.BR": {
    "city": "Breda",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "BRU",
    "industry": "Biotechnology",
    "long_name": "argenx SE",
    "market": "be_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ARGENX SE",
    "state": null,
    "summary": "argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.",
    "website": "http://www.argenx.com",
    "zipcode": "4811 AH"
  },
  "ARGX.VI": {
    "city": "Breda",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Biotechnology",
    "long_name": "argenx SE",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "ARGENX SE",
    "state": null,
    "summary": "argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.",
    "website": "http://www.argenx.com",
    "zipcode": "4811 AH"
  },
  "ESP.AS": {
    "city": "Amsterdam",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "AMS",
    "industry": "Medical Care Facilities",
    "long_name": "Esperite N.V.",
    "market": "nl_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ESPERITE",
    "state": null,
    "summary": "Esperite N.V., together with its subsidiaries, operates as a regenerative and predictive medicine company in the Netherlands, Spain, Italy, Switzerland, and internationally. It operates through four segments: Stem Cell, The Cell Factory, Genoma, and Other. The company collects, processes, and stores human adult stem cells from the umbilical cord blood and the umbilical cord. It also provides proteomics and genomics predictive medicines; and implements its proprietary technology for clinical grade production of autologous mesenchymal and stromal stem cells. In addition, it develops AGAATA, a diagnostic system based on the next generation sequencing technology, as well as allows laboratories to perform their own genetic analysis with the bioinformatics and methods developed by Genoma. The company's products portfolio includes Tranquility, a non-invasive prenatal test; and Cryosave's whole genome sequencing, carrier screening tests, and other products. Further, it engages in biobanking cord blood and cord tissue stem cells business. The company was formerly known as Cryo-Save Group N.V. and changed its name to Esperite N.V. in July 2014. Esperite N.V. was founded in 2000 and is headquartered in Amsterdam, the Netherlands.",
    "website": "http://www.esperite.com",
    "zipcode": "1016 BX"
  },
  "IGPH.SW": {
    "city": "Hoofddorp",
    "country": "Netherlands",
    "currency": "CHF",
    "exchange": "EBS",
    "industry": "Diagnostics & Research",
    "long_name": "IGEA Pharma N.V.",
    "market": "ch_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "IGEA Pharma N",
    "state": null,
    "summary": "IGEA Pharma N.V. commercializes health-tech and med-tech products and devices in in the United States. The company offers Alz1, an at-home lab test kit to measure non-bound copper in the blood; and dietary supplement products to reduce blood heavy metals content under the Alz1 Tab brand. It also provides dry aerosol generators for air and inanimate environmental surfaces sanitization, as well as air sterilization and purification devices. The company also engages in laboratory analysis. IGEA Pharma N.V. was incorporated in 2015 and is headquartered in Hoofddorp, the Netherlands.",
    "website": "http://www.igeapharma.nl",
    "zipcode": "2132 WT"
  },
  "K3P.F": {
    "city": "Amsterdam",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Kiadis Pharma N.V.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "KIADIS PHARMA NV  EO -,10",
    "state": null,
    "summary": "Kiadis Pharma N.V., a biopharmaceutical company, develops cell-based immunotherapy products in the field of blood building system. It develops K-NK002 as an adjunctive immunotherapeutic for blood cancer patients undergoing a haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol; and K-NK003 for the treatment of patients with acute myeloid leukemia relapse/refractory. The company also develops K-NK-ID101 for the treatment of COVID-19 infection; and K-NK004 to treat multiple myeloma. In addition, it develops NK cell therapies for blood cancers and solid tumors. The company has a collaboration agreement with Sanofi. Kiadis Pharma N.V. was founded in 1997 and is headquartered in Amsterdam, the Netherlands. As of April 12, 2021, Kiadis Pharma N.V. operates as a subsidiary of Sanofi Foreign Participations B.V.",
    "website": "http://www.kiadis.com",
    "zipcode": "1105 BP"
  },
  "KDS.AS": {
    "city": "Amsterdam",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "AMS",
    "industry": "Biotechnology",
    "long_name": "Kiadis Pharma N.V.",
    "market": "nl_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "KIADIS",
    "state": null,
    "summary": "Kiadis Pharma N.V., a biopharmaceutical company, develops cell-based immunotherapy products in the field of blood building system. It develops K-NK002 as an adjunctive immunotherapeutic for blood cancer patients undergoing a haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol; and K-NK003 for the treatment of patients with acute myeloid leukemia relapse/refractory. The company also develops K-NK-ID101 for the treatment of COVID-19 infection; and K-NK004 to treat multiple myeloma. In addition, it develops NK cell therapies for blood cancers and solid tumors. The company has a collaboration agreement with Sanofi. Kiadis Pharma N.V. was founded in 1997 and is headquartered in Amsterdam, the Netherlands. As of April 12, 2021, Kiadis Pharma N.V. operates as a subsidiary of Sanofi Foreign Participations B.V.",
    "website": "http://www.kiadis.com",
    "zipcode": "1105 BP"
  },
  "LVTX": {
    "city": "Utrecht",
    "country": "Netherlands",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Lava Therapeutics B.V.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "LAVA Therapeutics N.V.",
    "state": null,
    "summary": "Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of prostate cancer. Lava Therapeutics B.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of potential product candidates. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.",
    "website": "http://www.lavatherapeutics.com",
    "zipcode": "3584 CM"
  },
  "MRUS": {
    "city": "Utrecht",
    "country": "Netherlands",
    "currency": "USD",
    "exchange": "NGM",
    "industry": "Biotechnology",
    "long_name": "Merus N.V.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Merus N.V.",
    "state": null,
    "summary": "Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 for the pancreatic and lung cancer, and other solid tumors. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat autoimmune disease. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore potential combination therapies or indication. Merus N.V. has collaborations and license agreement with Loxo Oncology at Lilly to discover and research novel T-cell re-directing bispecific antibodies. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.",
    "website": "http://www.merus.nl",
    "zipcode": "3584 CM"
  },
  "PHAR": {
    "city": "Leiden",
    "country": "Netherlands",
    "currency": "USD",
    "exchange": "NGM",
    "industry": "Biotechnology",
    "long_name": "Pharming Group N.V.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Pharming Group N.V.",
    "state": null,
    "summary": "Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has development collaboration and license agreement with Novartis. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",
    "website": "http://www.pharming.com",
    "zipcode": "2333 CR"
  },
  "PHARM.AS": {
    "city": "Leiden",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "AMS",
    "industry": "Biotechnology",
    "long_name": "Pharming Group N.V.",
    "market": "nl_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PHARMING GROUP",
    "state": null,
    "summary": "Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has development collaboration and license agreement with Novartis. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",
    "website": "http://www.pharming.com",
    "zipcode": "2333 CR"
  },
  "PHG": {
    "city": "Amsterdam",
    "country": "Netherlands",
    "currency": "USD",
    "exchange": "NYQ",
    "industry": "Diagnostics & Research",
    "long_name": "Koninklijke Philips N.V.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Koninklijke Philips N.V. NY Reg",
    "state": null,
    "summary": "Koninklijke Philips N.V. operates as a health technology company in North America, Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, diagnostic X-ray, and imaging components as well as integrated clinical solutions; integrated interventional systems, including interventional diagnostic and therapeutic devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation, and patient management solutions; data, analytics, and actionable workflow solutions; and connected care informatics solutions. In addition, it provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; male grooming and beauty products and solutions; and kitchen appliances, home care, and garment care products, as well as coffee machines. Koninklijke Philips N.V. has a partnership with openDoctor to deliver an integrated radiology patient engagement platform that leverages openDoctor's real-time online appointment scheduling services as part of its patient management solution; and a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.",
    "website": "http://www.philips.com",
    "zipcode": "1096 BC"
  },
  "PHG.F": {
    "city": "Leiden",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Pharming Group N.V.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PHARMING GRP SP. ADRS",
    "state": null,
    "summary": "Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has development collaboration and license agreement with Novartis. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",
    "website": "http://www.pharming.com",
    "zipcode": "2333 CR"
  },
  "PHGN.F": {
    "city": "Leiden",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Pharming Group N.V.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PHARMING GRP  EO-,01",
    "state": null,
    "summary": "Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has development collaboration and license agreement with Novartis. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",
    "website": "http://www.pharming.com",
    "zipcode": "2333 CR"
  },
  "PHGUF": {
    "city": "Leiden",
    "country": "Netherlands",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Pharming Group N.V.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PHARMING GROUP NV",
    "state": null,
    "summary": "Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has development collaboration and license agreement with Novartis. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",
    "website": "http://www.pharming.com",
    "zipcode": "2333 CR"
  },
  "PHI1.DE": {
    "city": "Amsterdam",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Diagnostics & Research",
    "long_name": "Koninklijke Philips N.V.",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "KONINKL. PHILIPS EO -,20",
    "state": null,
    "summary": "Koninklijke Philips N.V. operates as a health technology company in North America, Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, diagnostic X-ray, and imaging components as well as integrated clinical solutions; integrated interventional systems, including interventional diagnostic and therapeutic devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation, and patient management solutions; data, analytics, and actionable workflow solutions; and connected care informatics solutions. In addition, it provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; male grooming and beauty products and solutions; and kitchen appliances, home care, and garment care products, as well as coffee machines. Koninklijke Philips N.V. has a partnership with openDoctor to deliver an integrated radiology patient engagement platform that leverages openDoctor's real-time online appointment scheduling services as part of its patient management solution; and a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.",
    "website": "http://www.philips.com",
    "zipcode": "1096 BC"
  },
  "PHI1.F": {
    "city": "Amsterdam",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Koninklijke Philips N.V.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "KONINKL. PHILIPS EO -,20",
    "state": null,
    "summary": "Koninklijke Philips N.V. operates as a health technology company in North America, Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, diagnostic X-ray, and imaging components as well as integrated clinical solutions; integrated interventional systems, including interventional diagnostic and therapeutic devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation, and patient management solutions; data, analytics, and actionable workflow solutions; and connected care informatics solutions. In addition, it provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; male grooming and beauty products and solutions; and kitchen appliances, home care, and garment care products, as well as coffee machines. Koninklijke Philips N.V. has a partnership with openDoctor to deliver an integrated radiology patient engagement platform that leverages openDoctor's real-time online appointment scheduling services as part of its patient management solution; and a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.",
    "website": "http://www.philips.com",
    "zipcode": "1096 BC"
  },
  "PHIA.AS": {
    "city": "Amsterdam",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "AMS",
    "industry": "Diagnostics & Research",
    "long_name": "Koninklijke Philips N.V.",
    "market": "nl_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "PHILIPS KON",
    "state": null,
    "summary": "Koninklijke Philips N.V. operates as a health technology company in North America, Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, diagnostic X-ray, and imaging components as well as integrated clinical solutions; integrated interventional systems, including interventional diagnostic and therapeutic devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation, and patient management solutions; data, analytics, and actionable workflow solutions; and connected care informatics solutions. In addition, it provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; male grooming and beauty products and solutions; and kitchen appliances, home care, and garment care products, as well as coffee machines. Koninklijke Philips N.V. has a partnership with openDoctor to deliver an integrated radiology patient engagement platform that leverages openDoctor's real-time online appointment scheduling services as part of its patient management solution; and a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.",
    "website": "http://www.philips.com",
    "zipcode": "1096 BC"
  },
  "PHIA.F": {
    "city": "Amsterdam",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Koninklijke Philips N.V.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "KONINKL. PHILIPS ADR -,20",
    "state": null,
    "summary": "Koninklijke Philips N.V. operates as a health technology company in North America, Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, diagnostic X-ray, and imaging components as well as integrated clinical solutions; integrated interventional systems, including interventional diagnostic and therapeutic devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation, and patient management solutions; data, analytics, and actionable workflow solutions; and connected care informatics solutions. In addition, it provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; male grooming and beauty products and solutions; and kitchen appliances, home care, and garment care products, as well as coffee machines. Koninklijke Philips N.V. has a partnership with openDoctor to deliver an integrated radiology patient engagement platform that leverages openDoctor's real-time online appointment scheduling services as part of its patient management solution; and a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.",
    "website": "http://www.philips.com",
    "zipcode": "1096 BC"
  },
  "PHIA.MI": {
    "city": "Amsterdam",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "MIL",
    "industry": "Diagnostics & Research",
    "long_name": "Koninklijke Philips N.V.",
    "market": "it_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "PHILIPS",
    "state": null,
    "summary": "Koninklijke Philips N.V. operates as a health technology company in North America, Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, diagnostic X-ray, and imaging components as well as integrated clinical solutions; integrated interventional systems, including interventional diagnostic and therapeutic devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation, and patient management solutions; data, analytics, and actionable workflow solutions; and connected care informatics solutions. In addition, it provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; male grooming and beauty products and solutions; and kitchen appliances, home care, and garment care products, as well as coffee machines. Koninklijke Philips N.V. has a partnership with openDoctor to deliver an integrated radiology patient engagement platform that leverages openDoctor's real-time online appointment scheduling services as part of its patient management solution; and a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.",
    "website": "http://www.philips.com",
    "zipcode": "1096 BC"
  },
  "PHIA.VI": {
    "city": "Amsterdam",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Diagnostics & Research",
    "long_name": "Koninklijke Philips N.V.",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "PHILIPS NV",
    "state": null,
    "summary": "Koninklijke Philips N.V. operates as a health technology company in North America, Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, diagnostic X-ray, and imaging components as well as integrated clinical solutions; integrated interventional systems, including interventional diagnostic and therapeutic devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation, and patient management solutions; data, analytics, and actionable workflow solutions; and connected care informatics solutions. In addition, it provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; male grooming and beauty products and solutions; and kitchen appliances, home care, and garment care products, as well as coffee machines. Koninklijke Philips N.V. has a partnership with openDoctor to deliver an integrated radiology patient engagement platform that leverages openDoctor's real-time online appointment scheduling services as part of its patient management solution; and a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.",
    "website": "http://www.philips.com",
    "zipcode": "1096 BC"
  },
  "PHIAN.MX": {
    "city": "Amsterdam",
    "country": "Netherlands",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Medical Laboratories & Research",
    "long_name": "Koninklijke Philips N.V.",
    "market": "mx_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "KONINKLIJKE PHILIPS NV",
    "state": null,
    "summary": "Koninklijke Philips N.V. operates as a health technology company in North America, Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, diagnostic X-ray, and imaging components as well as integrated clinical solutions; integrated interventional systems, including interventional diagnostic and therapeutic devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation, and patient management solutions; data, analytics, and actionable workflow solutions; and connected care informatics solutions. In addition, it provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; male grooming and beauty products and solutions; and kitchen appliances, home care, and garment care products, as well as coffee machines. Koninklijke Philips N.V. has a partnership with openDoctor to deliver an integrated radiology patient engagement platform that leverages openDoctor's real-time online appointment scheduling services as part of its patient management solution; and a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.",
    "website": "http://www.philips.com",
    "zipcode": "1096 BC"
  },
  "PHVS": {
    "city": "Leiden",
    "country": "Netherlands",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Pharvaris B.V.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Pharvaris N.V.",
    "state": null,
    "summary": "Pharvaris B.V., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.",
    "website": "http://www.pharvaris.com",
    "zipcode": "2333 CH"
  },
  "PRQR": {
    "city": "Leiden",
    "country": "Netherlands",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "ProQR Therapeutics N.V.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ProQR Therapeutics N.V.",
    "state": null,
    "summary": "ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.",
    "website": "http://www.proqr.com",
    "zipcode": "2333 Ck"
  },
  "QGEN": {
    "city": "Venlo",
    "country": "Netherlands",
    "currency": "USD",
    "exchange": "NYQ",
    "industry": "Diagnostics & Research",
    "long_name": "QIAGEN N.V.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Qiagen N.V.",
    "state": null,
    "summary": "QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay (IGRA) for TB testing, and assays for post-transplant testing and viral load monitoring; assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and assays for prenatal testing and detection of sexually transmitted diseases and HPV; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers PCR consumables, such as quantitative PCR, reverse transcription and combinations kits for analysis of gene expression, genotyping and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. It offers predefined and custom NGS gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.",
    "website": "http://www.qiagen.com",
    "zipcode": "5912 PL"
  },
  "QGEN.VI": {
    "city": "Venlo",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Diagnostics & Research",
    "long_name": "QIAGEN N.V.",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "QIAGEN NV",
    "state": null,
    "summary": "QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay (IGRA) for TB testing, and assays for post-transplant testing and viral load monitoring; assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and assays for prenatal testing and detection of sexually transmitted diseases and HPV; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers PCR consumables, such as quantitative PCR, reverse transcription and combinations kits for analysis of gene expression, genotyping and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. It offers predefined and custom NGS gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.",
    "website": "http://www.qiagen.com",
    "zipcode": "5912 PL"
  },
  "QIA.DE": {
    "city": "Venlo",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Diagnostics & Research",
    "long_name": "QIAGEN N.V.",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "QIAGEN NV  EO -,01",
    "state": null,
    "summary": "QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay (IGRA) for TB testing, and assays for post-transplant testing and viral load monitoring; assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and assays for prenatal testing and detection of sexually transmitted diseases and HPV; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers PCR consumables, such as quantitative PCR, reverse transcription and combinations kits for analysis of gene expression, genotyping and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. It offers predefined and custom NGS gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.",
    "website": "http://www.qiagen.com",
    "zipcode": "5912 PL"
  },
  "QIA.F": {
    "city": "Venlo",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "QIAGEN N.V.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "QIAGEN NV  EO -,01",
    "state": null,
    "summary": "QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay (IGRA) for TB testing, and assays for post-transplant testing and viral load monitoring; assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and assays for prenatal testing and detection of sexually transmitted diseases and HPV; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers PCR consumables, such as quantitative PCR, reverse transcription and combinations kits for analysis of gene expression, genotyping and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. It offers predefined and custom NGS gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.",
    "website": "http://www.qiagen.com",
    "zipcode": "5912 PL"
  },
  "QURE": {
    "city": "Amsterdam",
    "country": "Netherlands",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "uniQure N.V.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "uniQure N.V.",
    "state": null,
    "summary": "uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.",
    "website": "http://www.uniqure.com",
    "zipcode": "1105 BP"
  },
  "RYLPF": {
    "city": "Amsterdam",
    "country": "Netherlands",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Diagnostics & Research",
    "long_name": "Koninklijke Philips N.V.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "KONINKLIJKE PHILIPS NV",
    "state": null,
    "summary": "Koninklijke Philips N.V. operates as a health technology company in North America, Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides magnetic resonance imaging, computed tomography, advanced molecular imaging, diagnostic X-ray, and imaging components as well as integrated clinical solutions; integrated interventional systems, including interventional diagnostic and therapeutic devices; imaging products focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. The company also offers monitoring and analytics solutions; sleep and respiratory care solutions; emergency care and resuscitation, and patient management solutions; data, analytics, and actionable workflow solutions; and connected care informatics solutions. In addition, it provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; male grooming and beauty products and solutions; and kitchen appliances, home care, and garment care products, as well as coffee machines. Koninklijke Philips N.V. has a partnership with openDoctor to deliver an integrated radiology patient engagement platform that leverages openDoctor's real-time online appointment scheduling services as part of its patient management solution; and a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.",
    "website": "http://www.philips.com",
    "zipcode": "1096 BC"
  },
  "SAE.DE": {
    "city": "Sevenum",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Shop Apotheke Europe N.V.",
    "market": "de_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SHOP APOTHEKE EUROPE INH.",
    "state": null,
    "summary": "Shop Apotheke Europe N.V. owns and operates online pharmacies in Germany, Belgium, Austria, Switzerland, the Netherlands, France, and Italy. It provides prescription medications, over-the-counter medications, and pharmacy-related beauty and personal care products, as well as food supplements. The company was founded in 2001 and is headquartered in Sevenum, the Netherlands.",
    "website": "http://shop-apotheke-europe.com",
    "zipcode": "5975 WD"
  },
  "SAE.F": {
    "city": "Sevenum",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Shop Apotheke Europe N.V.",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SHOP APOTHEKE EUROPE INH.",
    "state": null,
    "summary": "Shop Apotheke Europe N.V. owns and operates online pharmacies in Germany, Belgium, Austria, Switzerland, the Netherlands, France, and Italy. It provides prescription medications, over-the-counter medications, and pharmacy-related beauty and personal care products, as well as food supplements. The company was founded in 2001 and is headquartered in Sevenum, the Netherlands.",
    "website": "http://shop-apotheke-europe.com",
    "zipcode": "5975 WD"
  },
  "SAE1.F": {
    "city": "Sevenum",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Shop Apotheke Europe N.V.",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SHOP APOTH. UNSP.ADR/0,10",
    "state": null,
    "summary": "Shop Apotheke Europe N.V. owns and operates online pharmacies in Germany, Belgium, Austria, Switzerland, the Netherlands, France, and Italy. It provides prescription medications, over-the-counter medications, and pharmacy-related beauty and personal care products, as well as food supplements. The company was founded in 2001 and is headquartered in Sevenum, the Netherlands.",
    "website": "http://shop-apotheke-europe.com",
    "zipcode": "5975 WD"
  },
  "SAEYY": {
    "city": "Sevenum",
    "country": "Netherlands",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Shop Apotheke Europe N.V.",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SHOP APOTHEKE EUROPE NV UNSPON ",
    "state": null,
    "summary": "Shop Apotheke Europe N.V. owns and operates online pharmacies in Germany, Belgium, Austria, Switzerland, the Netherlands, France, and Italy. It provides prescription medications, over-the-counter medications, and pharmacy-related beauty and personal care products, as well as food supplements. The company was founded in 2001 and is headquartered in Sevenum, the Netherlands.",
    "website": "http://shop-apotheke-europe.com",
    "zipcode": "5975 WD"
  },
  "SHOP.VI": {
    "city": "Sevenum",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Pharmaceutical Retailers",
    "long_name": "Shop Apotheke Europe N.V.",
    "market": "at_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SHOP APOTHEKE EUROPE NV",
    "state": null,
    "summary": "Shop Apotheke Europe N.V. owns and operates online pharmacies in Germany, Belgium, Austria, Switzerland, the Netherlands, France, and Italy. It provides prescription medications, over-the-counter medications, and pharmacy-related beauty and personal care products, as well as food supplements. The company was founded in 2001 and is headquartered in Sevenum, the Netherlands.",
    "website": "http://shop-apotheke-europe.com",
    "zipcode": "5975 WD"
  },
  "UQ1.DE": {
    "city": "Amsterdam",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Biotechnology",
    "long_name": "uniQure N.V.",
    "market": "de_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "UNIQURE N.V.  EO -,05",
    "state": null,
    "summary": "uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.",
    "website": "http://www.uniqure.com",
    "zipcode": "1105 BP"
  },
  "UQ1.F": {
    "city": "Amsterdam",
    "country": "Netherlands",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "uniQure N.V.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "UNIQURE N.V.  EO -,05",
    "state": null,
    "summary": "uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.",
    "website": "http://www.uniqure.com",
    "zipcode": "1105 BP"
  }
}
